R
Ray Kim
Researcher at Mayo Clinic
Publications - 13
Citations - 2766
Ray Kim is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Liver disease & Model for End-Stage Liver Disease. The author has an hindex of 8, co-authored 11 publications receiving 2539 citations.
Papers
More filters
Journal ArticleDOI
Model for end-stage liver disease (MELD) and allocation of donor livers
Russell H. Wiesner,Erick B. Edwards,Richard B. Freeman,Ann M. Harper,Ray Kim,Patrick S. Kamath,Walter K. Kremers,John R. Lake,Todd K. Howard,Robert M. Merion,Robert A. Wolfe,Ruud A.F. Krom,Paul M. Colombani,Paige C. Cottingham,Stephen P. Dunn,John J. Fung,Douglas W. Hanto,Sue V. McDiarmid,John M. Rabkin,Lewis W. Teperman,Jeremiah G. Turcotte,Lynn Rothberg Wegman +21 more
TL;DR: Data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.
Journal ArticleDOI
Hepatic Resection of Hepatocellular Carcinoma in Patients With Cirrhosis: Model of End-Stage Liver Disease (MELD) Score Predicts Perioperative Mortality
Swee H. Teh,John D. Christein,John H. Donohue,Florencia G. Que,Michael L. Kendrick,Michael B. Farnell,Stephen S. Cha,Patrick S. Kamath,Ray Kim,David M. Nagorney +9 more
TL;DR: MELD score was a strong predictor of both perioperative mortality and long-term survival in patients with cirrhosis undergoing hepatic resection for HCC and other treatment modalities should be considered.
Journal ArticleDOI
The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States
TL;DR: This study confirms that birth cohort testing is, on average, cost‐effective, however, this remains true only when enough tested and HCV‐positive subjects are treated to generate sufficient cost offsets and QALY gains.
Journal ArticleDOI
Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites
Paolo Angeli,Arun J. Sanyal,Sören Möller,Carlo Alessandria,Adrián Gadano,Ray Kim,Shiv Kumar Sarin,Mauro Bernardi +7 more
TL;DR: This article reviews critically the current knowledge and it outlines future perspectives, on the management of renal dysfunction in patients with cirrhosis.
Journal ArticleDOI
Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C
TL;DR: This study aimed to review structural frameworks and key model parameters as reported in current economic evaluations for treatments for chronic hepatitis C, and model the impact of variability across parameters on results.